Enclomiphene citrate has attracted considerable scientific interest for its ability to stimulate the body’s natural testosterone production.
Unlike externally administered testosterone, Enclomiphene works through the body’s existing hormonal signalling system, encouraging the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH).
Human clinical trials have demonstrated impressive increases in testosterone, with some study groups recording improvements exceeding 100% from baseline.
Testosterone More Than Doubled in Clinical Research
A particularly notable 2014 Phase IIb clinical trial investigated Enclomiphene in men with secondary hypogonadism.
After three months, researchers recorded the following average testosterone concentrations:
| Experimental group | Starting testosterone | After 3 months | Approximate increase |
|---|---|---|---|
| Enclomiphene 12.5 mg | 217 ng/dL | 472 ng/dL | +117% |
| Enclomiphene 25 mg | 210 ng/dL | 406 ng/dL | +93% |
| Testosterone gel | 210 ng/dL | 463 ng/dL | +120% |
Both Enclomiphene groups demonstrated statistically significant increases in testosterone.
The 12.5 mg group recorded a particularly impressive improvement of approximately 117%, illustrating the compound’s ability to stimulate endogenous testosterone production under controlled clinical conditions.
Read the 2014 Enclomiphene clinical study.
Why Did 12.5 mg Produce Higher Testosterone Than 25 mg?
Interestingly, the 12.5 mg group achieved a higher average testosterone concentration than the 25 mg group in this particular investigation.
However, this does not establish that the lower dose was more effective.
The groups contained different participants, individual hormonal responses varied, and the study did not demonstrate statistical superiority of 12.5 mg over 25 mg.
Furthermore, an earlier pharmacological investigation found that 25 mg produced significantly greater LH stimulation than the lower experimental doses.
These findings highlight an interesting characteristic of Enclomiphene research: testosterone responses do not necessarily increase in direct proportion to the amount administered.
Read the Enclomiphene pharmacodynamic investigation.
Larger Trials Confirmed Encouraging Hormonal Results
Two subsequent Phase III investigations provided further evidence of Enclomiphene’s testosterone-stimulating activity.
Following 16 weeks of treatment, researchers reported increased testosterone concentrations alongside higher LH and FSH levels in men with secondary hypogonadism.
An especially interesting finding was that sperm concentrations remained within the normal range in the Enclomiphene groups.
By comparison, testosterone gel also increased circulating testosterone but reduced LH, FSH and sperm production.
This distinction demonstrates Enclomiphene’s ability to support endogenous hormonal signalling rather than simply replacing circulating testosterone.
Read the Phase III Enclomiphene research.
What Did the 2025 Scientific Review Reveal?
A 2025 systematic review and meta-analysis examined randomised trials involving Enclomiphene and Clomiphene in men with low testosterone.
Across the combined studies, treatment was associated with an average testosterone concentration approximately 274 ng/dL higher than placebo.
Significant increases in LH and FSH were also recorded.
Although the analysis included both compounds rather than Enclomiphene alone, its findings reinforced the encouraging hormonal responses demonstrated in earlier clinical investigations.
Read the 2025 systematic review.
Final Thoughts
Enclomiphene has demonstrated substantial testosterone-raising activity across multiple controlled human investigations.
The results are particularly noteworthy because significant increases in testosterone occurred alongside stimulation of the body’s natural reproductive hormone pathways.
From testosterone more than doubling in one clinical study group to the consistent hormonal improvements demonstrated in larger trials, Enclomiphene has established a compelling foundation for continued endocrine research.
Individual responses vary, and the findings cannot be used to determine an optimal dose or predict results in healthy men.
For a broader examination of its mechanisms and clinical development, visit our Complete Enclomiphene Research Guide.
Research Use Only: Enclomiphene is an investigational compound without UK marketing authorisation. Its testosterone-raising effects have been demonstrated in selected clinical populations, but long-term safety and improvements in patient symptoms require further investigation.
